DUBLIN--(BUSINESS WIRE)--The "Disease Analysis: Asthma - Forecast and Market Analysis" report has been added to ResearchAndMarkets.com's offering.
Asthma is a chronic respiratory condition characterized by recurrent wheezing, coughing, and breathlessness, which occur in acute events known as exacerbations. Often triggered by factors such as exercise, allergen or irritant exposure, change in weather, or viral respiratory infections, these flare-ups can vary significantly in frequency and severity.
Attacks consist of swelling of the lining of the bronchial tubes, which narrows airways and results in a reduction of airflow into and out of the lungs. Historically considered to be a single disease, asthma is now viewed more as an overlapping assemblage of individual phenotypes with various underlying pathophysiological processes leading to symptoms.
Latest Key Takeaways
- The publisher estimates that in 2018, there were approximately 343.6 million prevalent cases of asthma in individuals aged up to 44 years worldwide, and forecasts that number to increase to 363.7 million prevalent cases by 2027.
- The GINA treatment strategy released in 2019 included an important change disrupting a fundamental practice in mild asthma management. Treatment with a short-acting beta 2 agonist (SABA) alone is no longer recommended for adults and adolescents with asthma. While short-acting bronchodilators may provide symptom relief for patients, they remain at risk for severe exacerbations.
- The majority of approved drugs in the asthma space are inhaled small molecules, while several newer approvals show a shift towards development of injectable biologics.
- Since its launch as the first fixed-dose combination (FDC) of an inhaled corticosteroid (ICS) and a long-acting beta 2 agonist (LABA), GlaxoSmithKline's Advair has become a well-established gold-standard therapy in asthma. However, generic competition in Europe, and more recently in the US, marks the end of this successful history.
- Novartis has ended development of its asthma drug fevipiprant following data which showed that the once-daily pill was not effective.
- The convenience of pipeline ICS/LABA/long-acting muscarinic antagonist (LAMA) triple FDC therapies will only marginally increase the overall use of the LAMA drug class as physicians remain skeptical about the role of LAMAs in asthma.
- Key upcoming catalysts in asthma include topline results from Phase III studies for SABA/ICS combination PT027.
Key Topics Covered:
OVERVIEW
- Latest key takeaways
DISEASE BACKGROUND
- Definition
- Patient segmentation
TREATMENT
- Main pharmacological treatments are categorized as controllers or relievers
- Treatment guidelines recommend step-up therapy
- Reliever medications have traditionally consisted of SABAs
- Controller medications are dominated by ICSs and LABAs
- Concomitant use of additional treatments may be considered
- Add-on treatment for severe asthma has become highly personalized
- New recommendations upend decades of routine asthma management
- COVID-19 recommendations for asthma management
EPIDEMIOLOGY
- Prevalence methodology
MARKETED DRUGS
PIPELINE DRUGS
KEY REGULATORY EVENTS
- Teva Seeks To Simplify With Canadian Inhalers
- Teva Completes 'Digihaler Family'
- Perrigo's Albuterol Advantage Blunted By Recall
- GSK's Trelegy Ellipta Is First Triple Combination Approved For Asthma In the US
- US Albuterol Market Hots Up With Lupin ProAir Approval
- Aurobindo's US Respiratory Filing Could Rival Teva's Qvar
- Genentech Seeks Self-Administration Option For Xolair
- Teva Launches ProAir Dry Powder Digital Inhaler
- Novartis Triple Combo Enerzair Gets EU OK For Asthma
- Japan Nods For Enerzair And Atectura For Asthma
- Cipla Files ANDA For Advair Rival
- Mylan Launches Advair Rival In Canada
- England's NICE Says No To Sanofi's Dupixent For Asthma
- US FDA Orders Singulair Boxed Warning On Neuropsychiatric Events Despite 'Limited' Evidence
- Canada Explains Studies Needed For Subsequent-Entry Orally Inhaled Products
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
- Allergy Therapeutics Takes First Steps Into Broader Vaccine Field
- Lannett Makes Deal For Respirent's Flovent Diskus Rival
- Chiesi Gets Bayer To Co-Promote Respiratory Drugs In China
- GSK Sells Lesser Consumer Brands With Little Fanfare As Part Of Major Plan For Global Lead
- Yuhan Partners With GI Innovation On Next-Generation Allergy Treatment
- Iconovo And Amneal Collaborate On Symbicort Rival
- LEO Pays $40m For Novel Dermatitis, Asthma Candidate
CLINICAL TRIAL LANDSCAPE
- Sponsors by status
- Sponsors by phase
- Recent events
DRUG ASSESSMENT MODEL
ICSs
ICS/LABAs
ICS/LABA/LAMAs
- Other oral classes
- Biologics
MARKET DYNAMICS
FUTURE TRENDS
- High biologic prices will translate to high revenues, despite restricted prescribing
- The ICS/LABA class will remain dominant by patient share, as first-generation products lose share to follow-on products and generics
- Skepticism regarding the role of LAMAs in asthma may blunt uptake of triple therapies
CONSENSUS FORECASTS
RECENT EVENTS AND ANALYST OPINION
- Tezepelumab for Asthma (November 10, 2020)
- GB001 for Asthma (October 13, 2020)
- QAW039 for Asthma (December 16, 2019)
- Seliforant for Asthma (December 2, 2019)
- Masitinib for Asthma (November 7, 2019)
- QAW039 for Asthma (October 22, 2019)
- Atectura Breezhaler for Asthma (September 30, 2019)
- Enerzair Breezhaler for Asthma (September 30, 2019)
- Trimbow for Asthma (September 30, 2019)
- Multiple Drugs for Asthma (June 25, 2019)
- REGN3500 for Asthma (June 21, 2019)
KEY UPCOMING EVENTS
KEY OPINION LEADER INSIGHTS
BIBLIOGRAPHY
- Prescription information
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/6sbmh6
